Literature DB >> 10361140

Normal human serum contains natural antibodies reactive with autologous ABO blood group antigens.

S H Spalter1, S V Kaveri, E Bonnin, J C Mani, J P Cartron, M D Kazatchkine.   

Abstract

It is widely accepted that the serum of healthy individuals contains natural antibodies only against those blood group A or B antigens that are not expressed on the individual's red blood cells. The mechanisms involved in tolerance to autologous blood group antigens remain unclear. In the present study, we show that IgM and IgG antibodies reactive with autologous blood group antigens are present in the immunoglobulin fraction of normal human serum. Natural IgG anti-A antibodies purified by affinity chromatography from IgG of individuals of blood group A exhibited an affinity for A trisaccharide antigen in the micromolar range and agglutinated A red cells at sixfold higher concentrations than those required for agglutination with affinity-purified anti-A IgG of individuals of blood group B. Whereas autoantibodies reactive with self A and B antigens are readily detected in purified IgG and IgM fractions, their expression is restricted in whole serum as a result of complementary interactions between variable regions of antibodies. These observations suggest that tolerance to autologous ABO blood group antigens is dependent on peripheral control of antibody autoreactivity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10361140

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

Review 1.  Universal pathogen-reduced plasma in elective open-heart surgery and liver resection.

Authors:  Bjarte G Solheim
Journal:  Clin Med Res       Date:  2006-09

Review 2.  Blood stains of the Turin Shroud 2015: beyond personal hopes and limitations of techniques.

Authors:  Giovanni Di Minno; Rosanna Scala; Itala Ventre; Giovanni de Gaetano
Journal:  Intern Emerg Med       Date:  2016-03-21       Impact factor: 3.397

3.  Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin.

Authors:  Charles C Chu; Rosa Catera; Lu Zhang; Sebastien Didier; Briana M Agagnina; Rajendra N Damle; Matthew S Kaufman; Jonathan E Kolitz; Steven L Allen; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2010-01-28       Impact factor: 22.113

Review 4.  Manipulation of the glycan-specific natural antibody repertoire for immunotherapy.

Authors:  J Stewart New; R Glenn King; John F Kearney
Journal:  Immunol Rev       Date:  2016-03       Impact factor: 12.988

Review 5.  The origin of anti-GM1 antibodies in neuropathies: the "binding site drift" hypothesis.

Authors:  Pablo H H Lopez; Ricardo D Lardone; Fernando J Irazoqui; Mariana Maccioni; Gustavo A Nores
Journal:  Neurochem Res       Date:  2002-08       Impact factor: 3.996

Review 6.  Current Perspectives in ABO-Incompatible Kidney Transplant.

Authors:  Federica Maritati; Claudia Bini; Vania Cuna; Francesco Tondolo; Sarah Lerario; Valeria Grandinetti; Marco Busutti; Valeria Corradetti; Gaetano La Manna; Giorgia Comai
Journal:  J Inflamm Res       Date:  2022-05-25

Review 7.  Strategies to overcome the ABO barrier in kidney transplantation.

Authors:  Georg A Böhmig; Andreas M Farkas; Farsad Eskandary; Thomas Wekerle
Journal:  Nat Rev Nephrol       Date:  2015-09-01       Impact factor: 28.314

8.  Genotyping of samples lacking expected antibodies in ABO blood group.

Authors:  Zhi-Hui Deng; Jian-Qiang Zeng; Qiong Yu; Yu-Qing Su; Yan-Lian Liang; Liang Lu; Wei-Gang Zhu; Bao-Cheng Yang
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

Review 9.  On the dark side of therapies with immunoglobulin concentrates: the adverse events.

Authors:  Peter J Späth; Guido Granata; Fabiola La Marra; Taco W Kuijpers; Isabella Quinti
Journal:  Front Immunol       Date:  2015-02-05       Impact factor: 7.561

Review 10.  Tumor-Associated Glycans and Immune Surveillance.

Authors:  Behjatolah Monzavi-Karbassi; Anastas Pashov; Thomas Kieber-Emmons
Journal:  Vaccines (Basel)       Date:  2013-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.